Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double Blind, Placebo and Active Controlled, Parallel Study to Evaluate the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Double Blind, Placebo and Active Controlled, Parallel Study to Evaluate the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isavuconazonium (Primary) ; Moxifloxacin
  • Indications Aspergillosis; Candidiasis; Zygomycosis
  • Focus Adverse reactions
  • Acronyms SECURE
  • Sponsors Astellas Pharma

Most Recent Events

  • 29 Apr 2021 Results of post-hoc analysis of two studies (SECURE & VITAL) published in the Clinical Infectious Diseases.
  • 19 Nov 2020 Data were used from SECURE and VITAL studies to assess Cost-Effectiveness of Isavuconazole in the Treatment of Invasive Fungal Infections in Portugal presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 12 Nov 2018 Results assessing exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial published in the Journal of Antimicrobial Chemotherapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top